Search 

Medherant develops patches for transdermal drug delivery using our proprietary TEPI-Patch® technology. Key advantages of the TEPI Patch® technology over current technologies include excellent adhesion that can be tailored for up to 7-days of drug delivery, whilst still being easy and painless to remove.  

The TEPI Patch® provides a better experience for the user as it does not leave a residue or dirty mark around the patch – referred to as ‘cold flow’. No organic solvents are involved in manufacture of this drug-in-adhesive system.

As well as developing our own products, some of which have already been successfully tested in clinical studies, Medherant is working with pharmaceutical companies to develop new products. We are seeking additional partners and can offer rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of drugs of interest.

MediWales is the life science network and representative body for Wales.
An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.

MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally. 

Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins.